Methylprednisolone
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Methylprednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Methylprednisolone is a corticosteroid marketed in the US as oral tablets and injectable suspensions. The TxGNN model predicts it may be effective for alopecia areata. Of the 17 trials retrieved, only 1 directly tests methylprednisolone in this disease (Phase 4, n=42). The 20 publications are mostly retrospective or open-label studies and reviews, with no Phase 3 RCT.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Based on general pharmacology, methylprednisolone is a glucocorticoid receptor agonist with broad anti-inflammatory and immunosuppressive effects.
Alopecia areata is a T-cell-mediated autoimmune attack on the hair follicle, so suppressing that immune response is a plausible treatment approach. Pulse-dose corticosteroids (oral or intravenous) are already used clinically in severe or extensive cases.
The main concerns raised in the pulse-therapy reviews are relapse after tapering and the adverse effects of steroids. The mechanistic link rests on general glucocorticoid pharmacology, not on drug-specific mechanism data.
Clinical Trial Evidence
Only 3 of the 17 retrieved trials relate to alopecia. Most of the rest concern systemic lupus erythematosus with other drugs, and one concerns headache nerve blocks. They appear to be keyword-overlap hits and are not listed.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata. The design (controlled or single-arm) cannot be confirmed, so it is not counted as Phase 3-level evidence. |
| NCT07101471 | N/A | Completed | 296 | Observational, single-arm study of tofacitinib in alopecia. Some participants also received adjuvant prednisolone, so it is indirect evidence for steroids. |
| NCT01017510 | N/A | Unknown | 20 | Compares needle-free (DERMOJET) and standard syringe intralesional steroid injection in alopecia areata. It concerns delivery technique, not methylprednisolone specifically. |
Literature Evidence
No RCTs were found. The table lists the 10 most relevant of the 20 publications, chosen for direct methylprednisolone use in alopecia areata and study type.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews efficacy, relapse rates, side effects, and response predictors of corticosteroid pulse therapy in alopecia areata. |
| 35986630 | 2022 | Retrospective cohort | Dermatol Ther | 26 patients with extensive AA: methylprednisolone alone (14) vs methylprednisolone plus methotrexate (12). |
| 30745958 | 2019 | Clinical study | Open Access Maced J Med Sci | Methotrexate combined with mini-pulse methylprednisolone in severe AA (Vietnamese experience). |
| 25872976 | 2015 | Clinical study | Pediatr Dermatol | High relapse rates despite early IV methylprednisolone pulse therapy in severe childhood AA. |
| 25566921 | 2015 | Clinical study | Indian J Dermatol Venereol Leprol | IV methylprednisolone pulse therapy in severe AA. |
| 23336179 | 2014 | Clinical study | J Dermatol Treat | Pulse methylprednisolone proposed as a safer alternative to long-term systemic steroids in extensive AA. |
| 22426909 | 2012 | Clinical study | Saudi Med J | Intensive oral mega-pulse regimen in severe therapy-resistant AA. The provided abstract states only the aim. |
| 21592197 | 2011 | Clinical study | J Dermatol | Prognostic factors for response to methylprednisolone pulse therapy, aimed at defining proper indications. |
| 12746668 | 2003 | Open prospective study | Ann Dermatol Venereol | Open study of 66 patients with monthly IV methylprednisolone pulses in severe AA. |
| 9777767 | 1998 | Open prospective study | J Am Acad Dermatol | Open study of 45 patients with a single IV methylprednisolone pulse in AA of under 12 months’ duration. |
US Market Information
Methylprednisolone has 20 US authorizations. The provided data contains no approved-indication text. The table lists 5 of them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA011757 | Depo-Medrol | Injection, suspension | Pharmacia & Upjohn Company LLC |
| NDA011153 | Methylprednisolone | Tablet | Mylan Pharmaceuticals Inc. |
| ANDA210043 | Methylprednisolone acetate | Injection, suspension | Amneal Pharmaceuticals LLC |
| ANDA204072 | Methylprednisolone | Tablet | REMEDYREPACK INC. |
| ANDA206751 | Methylprednisolone | Tablet | Advanced Rx Pharmacy of Tennessee, LLC |
Both oral (tablet) and injectable (suspension) forms are available. This covers the oral pulse regimens studied in alopecia areata. The IV pulse regimens in the literature use intravenous methylprednisolone, which is not among the listed forms. Route compatibility has not been assessed.
Safety Considerations
Please refer to the package insert for safety information. The pulse-therapy literature identifies relapse after tapering and steroid adverse effects as the main concerns.
Conclusion and Next Steps
Decision: Hold
Rationale: Alopecia areata has a plausible mechanism, a completed Phase 4 study, and a body of pulse-therapy studies (L3). However, the evidence is mostly retrospective or open-label, with high relapse rates reported. No Phase 3 RCT exists. The package insert safety review is a blocking data gap, so the candidate cannot proceed to safety screening yet.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking gap)
- Detailed mechanism of action data
- The design and results of NCT01167946 (controlled or single-arm)
- A controlled trial, or a systematic review, of methylprednisolone pulse therapy against placebo or another treatment
- A plan for relapse after tapering and for steroid safety monitoring
- Assessment of route compatibility for IV pulse regimens
Other predictions: The other predictions in the pack are much weaker. Idiopathic steroid-sensitive nephrotic syndrome (rank 10) also reaches L3, but it is already a steroid-standard-of-care disease, so it is not a strong repurposing signal. Ranks 2 to 9 are L4 to L5 (model prediction only or off-target literature) and should stay on Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.